STOCKNO.DE
Institutional ownership intelligence
Schedule 13G/A

OCUL Schedule 13G/A filing by BlackRock

BlackRock reported beneficial ownership of 10.2M shares, representing 12% of OCULAR THERAPEUTIX INC in this filing.

FiledOct 17, 2025
Ownership dateSep 30, 2025
Reported shares10.2M
Reported ownership12%
Ownership details

Voting and dispositive power reported in the filing

These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.

Sole voting power 10.0M
Shared voting power 10.2M
Sole dispositive power 10.2M
Shared dispositive power 10.2M
Compared with the prior filing

How the reported position changed

This compares the current filing with the previous tracked Schedule 13 filing from the same reporting CIK for OCUL. A change between filings does not by itself establish when shares were bought or sold.

Previous filingNov 8, 2024
Reported share change-1,183,932
Ownership percentage change+4.7 pts
Previous filingThis filing
Reported shares11.4M10.2M
Reported ownership7.3%12%
Price context

Price dates alongside the ownership filing

Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.

Close near filing date$11.84as of Oct 17, 2025
Latest tracked price$8.64as of Aug 5, 2026
Source

Original filing and accession

Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.

Reporting filer
BlackRock
CIK
CIK0002012383
Accession
0002012383-25-002681
Form
Schedule 13G/A
Read the filing in context

Understand what a Schedule 13 filing does—and does not—tell you.